T2 Biosystems to Present at the 2017 Marcum Microcap Conference

LEXINGTON, Mass., June 08, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the 2017 Marcum Microcap Conference. The conference is being held June 15-16, 2017 at the Grand Hyatt Hotel in New York City.

Management is scheduled to present on Thursday, June 15, 2017 at 4:30 p.m. ET and will be available for one-on-one meetings during the conference.

About T2 Biosystems
T2 Biosystems is dedicated to developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida® Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
[email protected]
603-553-5803

Media Contact:
Matthew McKillip, T2 Biosystems
[email protected]
518-577-3466

Investor Contact:
Tucker Elcock, Teneo Strategy
[email protected]
212-886-9319